<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Transgender Youth on Hormone Therapy Risk Substantial Bone Loss

Default sub title

minute read

by Medscape | July 8, 2022
placeholder

Among transgender youth who receive puberty-delaying or gender-affirming hormone therapy, bone mineral density (BMD) is lower relative to age-based norms, and this is true regardless of gender assignment at birth.

Topics: Press Coverage